The stock of INNOVATION PHARMACEUTICALS INC (OTCMKTS:IPIX) registered an increase of 4.4% in short interest. IPIX’s total short interest was 548,500 shares in September as published by FINRA. Its up 4.4% from 525,400 shares, reported previously. With 633,700 shares average volume, it will take short sellers 1 days to cover their IPIX’s short positions.

The stock decreased 4.62% or $0.006 during the last trading session, reaching $0.124. About 321,181 shares traded. Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) has 0.00% since September 13, 2018 and is . It has by 0.00% the S&P500.

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat cancer, antibiotics, and inflammatory disease. The company has market cap of $25.61 million. The firm focuses on the development of compounds, including Prurisol, an anti-psoriasis drug candidate that is in Phase II clinical trial; Brilacidin, an antibiotic candidate for the treatment of acute bacterial skin and skin structure infection, oral mucositis, and inflammatory bowel disease, and ulcerative proctitis; and Kevetrin, an anti-cancer compound that has completed Phase I clinical trial. It currently has negative earnings. In addition, the firm owns compounds, such as KM 391 for the treatment of autism; KM 277 to treat arthritis; KM 278 for the treatment of asthma; KM 362 to treat MS/ALS/ParkinsonÂ’s disease; KM-3174 for the treatment of cancer; and KM-732 for hypertensive emergency.

More notable recent Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) news were published by: which released: “Cellceutix (CTIX) presents at Biotech Showcase San Francisco – Seeking Alpha” on January 10, 2017, also with their article: “Cellceutix: Financing Partners Arrested For Alleged Ponzi Scheme, Company Faces Risk Of Death Spiral Liquidity Crunch – Seeking Alpha” published on January 17, 2017, published: “Cellceutix Thwarts Frivolous Class Action Attempt; Has The Rosen Law Firm Been Exposed? – Seeking Alpha” on June 10, 2016. More interesting news about Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) were released by: and their article: “Innovation Pharmaceuticals Stock May Be A Triple-Crown Winner With Brilacidin By Year End – Seeking Alpha” published on July 19, 2017 as well as‘s news article titled: “Innovation Pharma up 58% on Brilacidin license deal – Seeking Alpha” with publication date: July 22, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.